From Medscape News:
Inflammatory breast cancer (IBC) accounts for 1%-5% of all breast cancer cases but 10% of breast cancer deaths. Historically, 5-year survival in IBC has been less than 5% when treated with surgery or radiation therapy, increasing to 30%-40% with multimodal therapy that includes preoperative chemotherapy adequate to induce pathologic complete response (CR) before surgery.
Naoto T. Ueno, MD, PhD, Section Chief of Translational Breast Cancer Research and Executive Director of the University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Program in Houston, Texas, spoke to Janis C. Kelly at Medscape about current IBC diagnosis and treatment.
Please read the entire Medscape article here to get read Dr. Ueno’s answers to the following questions:
- What do you see as the most significant advances in understanding and treatment of IBC in recent years?
- Is the statin effect (if it exists) in IBC related to anti-inflammatory activity?
- Is delayed or missed diagnosis still a problem in IBC?
- What are the key steps in diagnosis of suspected IBC?
- What is the standard for IBC treatment at MD Anderson?
- What is on the horizon for IBC?
- How big is the MD Anderson team working on inflammatory breast cancer?
- How is the MD Anderson IBC program supported?